SCHEMBL29776818

SCHEMBL29776818

O=c1ccc(-c2cnc(OCC(F)(F)F)nc2)nn1Cc1cc(Cl)ccc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.42
▸ MEN1 O00255 5/20 0.41
▸ KMT2A Q03164 5/20 0.41
▸ TSHR P16473 1/20 0.36
▸ TRPV3 Q8NET8 1/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MET P08581 1/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23297304 1.00 TP53 (0.42) TP53MEN1KMT2ATSHRTRPV3
SCHEMBL23297240 0.86 MEN1 (0.47) TP53MEN1KMT2ATRPV3KDM4E
SCHEMBL23297255 0.84 HDAC1 (0.42) TP53MEN1KMT2ATSHRKDM4E
SCHEMBL23297282 0.84 MET (0.41) TP53MEN1KMT2AMETPDE4A
SCHEMBL29776797 0.84 MET (0.41) TP53MEN1KMT2AMETPDE4A
SCHEMBL29569968 0.84 MEN1 (0.38) TP53MEN1KMT2ATRPV3MET
SCHEMBL23558980 0.84 MEN1 (0.38) TP53MEN1KMT2ATRPV3MET
SCHEMBL29569985 0.82 MEN1 (0.43) TP53MEN1KMT2ATRPV3MET
SCHEMBL23559425 0.82 MEN1 (0.43) TP53MEN1KMT2ATRPV3MET
SCHEMBL23297298 0.82 MET (0.46) TP53MEN1KMT2ASMN1; SMN2MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240833-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-03-04 — — US disclosed
US-20230048816-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2023-02-16 — — US disclosed
US-11390606-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPECUTICS, INC. (US) 2022-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240833-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A TP53 4800/4885MEN1 4368/4885KMT2A 4169/4885
US-11390606-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A TP53 4800/4885MEN1 4368/4885KMT2A 4169/4885
US-20230048816-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A TP53 4800/4885MEN1 4368/4885KMT2A 4169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback